194 related articles for article (PubMed ID: 35125241)
1. Harnessing natural killer cells for the treatment of multiple myeloma.
Clara JA; Childs RW
Semin Oncol; 2022 Feb; 49(1):69-85. PubMed ID: 35125241
[TBL] [Abstract][Full Text] [Related]
2. Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren HG; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Cytotherapy; 2023 Jul; 25(7):763-772. PubMed ID: 37055320
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
[TBL] [Abstract][Full Text] [Related]
4. Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment.
Vu SH; Pham HH; Pham TTP; Le TT; Vo MC; Jung SH; Lee JJ; Nguyen XH
Front Oncol; 2023; 13():1275076. PubMed ID: 38023191
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.
Reina-Ortiz C; Giraldos D; Azaceta G; Palomera L; Marzo I; Naval J; Villalba M; Anel A
Cells; 2022 Jan; 11(3):. PubMed ID: 35159200
[TBL] [Abstract][Full Text] [Related]
6. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
[TBL] [Abstract][Full Text] [Related]
7. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
Alfarra H; Weir J; Grieve S; Reiman T
Front Immunol; 2020; 11():575609. PubMed ID: 33304346
[TBL] [Abstract][Full Text] [Related]
8. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
Pittari G; Vago L; Festuccia M; Bonini C; Mudawi D; Giaccone L; Bruno B
Front Immunol; 2017; 8():1444. PubMed ID: 29163516
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
10. NK cell therapy in relapsed refractory multiple myeloma.
Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
[TBL] [Abstract][Full Text] [Related]
11. [Research Progress of NK Cell Therapy in Multiple Myeloma Treatment --Review].
Han F; Xi YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):297-301. PubMed ID: 38387938
[TBL] [Abstract][Full Text] [Related]
12. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.
Cichocki F; Bjordahl R; Goodridge JP; Mahmood S; Gaidarova S; Abujarour R; Davis ZB; Merino A; Tuininga K; Wang H; Kumar A; Groff B; Witty A; Bonello G; Huffman J; Dailey T; Lee TT; Malmberg KJ; Walcheck B; Höpken U; Rehm A; Valamehr B; Miller JS
Nat Commun; 2022 Nov; 13(1):7341. PubMed ID: 36446823
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities.
Liu P; Jin Y; Sattar H; Liu H; Xie W; Zhou F
J Leukoc Biol; 2018 May; 103(5):821-828. PubMed ID: 29733502
[TBL] [Abstract][Full Text] [Related]
14. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
16. Potential of NK cells in multiple Myeloma therapy.
Khan AM; Devarakonda S; Bumma N; Chaudhry M; Benson DM
Expert Rev Hematol; 2019 Jun; 12(6):425-435. PubMed ID: 31070067
[No Abstract] [Full Text] [Related]
17. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cell therapy in multiple Myeloma.
Vallet S; Pecherstorfer M; Podar K
Expert Opin Biol Ther; 2017 Dec; 17(12):1511-1522. PubMed ID: 28857616
[TBL] [Abstract][Full Text] [Related]
19. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
[TBL] [Abstract][Full Text] [Related]
20. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
